V2X (VVX) has been awarded a position on the U.S. Navy’s Worldwide Expeditionary Multiple Award Contract 2.0, a key vehicle for delivering ...
Massachusetts is launching a first-of-its-kind statewide vehicle-to-everything (V2X) pilot program. This two-year initiative, backed by the Massachusetts Clean Energy Center (MassCEC), aims to ...
Learn how about WEXMAC 2.0 aims to simplify procurement processes and improve logistical support for joint forces and federal agencies.
V2X was formed by the $2.1 billion merger of Vertex and Vectrus in 2022 and has about 16,000 employees. Previously based in McLean, the company announced in December 2024 it had opened new corporate ...
Aerospace & Defense Analyst Madrid holds a meeting with management on March 13 hosted by BTIG. See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze, and ...
V2X has landed a $100 million firm-fixed-price contract from the U.S. Navy to provide support services to its Aegis Ashore facilities in Poland. The company said Tuesday the firm-fixed-price ...
RESTON, Va., March 11, 2025 /PRNewswire/ -- V2X, Inc. (NYSE: VVX) was awarded a new $100 million contract to support the U.S. Navy's Aegis Ashore facilities in Poland. These facilities are a ...
2025 Capital Expenditures: Approximately $30 million. V2X Inc (NYSE:VVX) reported record quarterly revenue, adjusted EBITDA, and cash flow for the fourth quarter of 2024. Revenue increased by 11% ...
GM has joined PG&E’s vehicle-to-everything (V2X) pilot program, enabling energy customers to bundle their GM Energy systems and eventually get paid to supply excess energy back to their local grid.
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...
In this article, we are going to take a look at where V2X, Inc. (NYSE:VVX) stands against the other defense stocks. The Ukraine crisis has taken an unexpected turn following a heated exchange at ...
Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.